Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A

SSSE:600671
15.05
CNY
-0.93
(-5.82%)
0.05EPS
230.41P/E
2.65BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.67
1.1
0.79
1.02
1.52
2.9
2.44
1.68
1.18
0.89
1
1.78
1.74
1.66
Basic EPS, GAAP
0.02
0.02
-0.18
0.01
0.07
-0.08
0.42
-0.33
-0.24
-0.55
-0.31
0.13
0.14
0.09
Free Cash Flow per Basic Share
0.01
-0.22
-0.12
-0.19
-0.32
0.27
0.55
-0.16
-0.25
-0.19
-0.24
-0.47
-0.16
- -
Dividend per Share
0.08
0.05
0.06
0.06
0.08
0.07
0.05
0.06
0.05
0.04
0.05
0.07
0.05
0.05
Book Value per Share
0.64
0.65
0.47
0.48
0.55
0.46
0.84
0.6
0.37
-0.12
0.3
0.43
0.57
0.64
Tangible Book Value per Share
0.56
0.59
0.4
0.41
0.3
-0.13
0.27
0.51
0.3
-0.18
0.24
0.38
0.52
0.59
Basic Weighted Avg Shares
105
136
120
122
116
123
122
123
124
122
122
122
122
122
Sales/Revenue/Turnover
281
149
95
124
176
358
297
207
147
109
122
217
212
203
Operating Margin (%)
3.01
5.53
-15.46
-3.29
-0.08
2.58
-2.96
-2.42
-12.43
-26.11
-17.97
15.74
8.11
9.43
Depreciation Expense
7
6
9
9
9
13
13
9
12
18
15
19
25
- -
Net Income, GAAP
2
3
-22
1
8
-10
51
-41
-30
-68
-38
15
18
12
Effective Tax Rate (%)
13.14
33.41
- -
37.27
22.27
- -
2.63
- -
- -
- -
- -
24.79
29.55
44.03
Profit Margin (%)
0.75
1.82
-22.73
0.98
4.62
-2.76
17.06
-19.61
-20.26
-62
-31.43
7.02
8.32
5.69
Working Capital
-12
-36
-82
-86
-23
-101
62
-32
-65
-97
-39
-64
-54
-45
LT Debt
- -
- -
- -
- -
46
7
37
5
5
7
7
10
9
11
Total Equity
95
85
63
66
97
89
133
93
65
5
56
85
94
101
Return on Invested Capital (%)
1.25
1.61
- -
-1.59
-5.2
- -
21.06
- -
- -
- -
- -
9.49
2.4
1.57
Return on Capital (%)
4.45
3.97
- -
2.44
6.26
- -
26.36
- -
- -
- -
- -
6.3
13.35
8.2
Return on Common Equity (%)
2.73
3.45
-31.7
2.1
12.91
-16.1
64.41
-46.4
-50.5
- -
- -
34.06
28.8
16.37

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
191
179
148
LT Borrowings
- -
- -
- -
LT Finance Leases
8
11
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
2,650
2,056
2,654

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
257
244
215
Cash, Cash Equivalents & STI
45
70
36
Accounts Receivable, Net
154
118
129
Inventories
42
39
36
Total Current Liabilities
306
290
260
Payables & Accruals
- -
- -
- -
ST Debt
191
179
148
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
112.97%
213.18%
10.55%
Free Cash Flow
-0.98%
16.88%
-66.13%
Net Income, GAAP
-61.86%
-13.49%
15.59%
Sales/Revenue/Turnover
16.17%
6.59%
-2.55%
Total Cash Common Dividend
2.69%
2.19%
-24.3%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28
32
65
93
217
2025
52
51
- -
53
212
2026
44
55
50
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.08
-0.07
0.12
0.16
0.13
2025
0.04
0.04
- -
0.03
0.14
2026
0.03
0.02
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.04
0.07
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Xue Jian Sun
Full Time Employees
392
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Boya Times Center Hangzhou ZH China 311215
IPO Date
Aug 23, 1993
Website
hztmyy.com
Business
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS) is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of proprietary Chinese medicines and chemical drugs. The company offers core products including Tianmushan brand tablets and capsules for cardiovascular, respiratory, and digestive system treatments; pediatric syrups and granules such as pediatric cough syrup and digestive aids; and external preparations like ointments for skin conditions, alongside active pharmaceutical ingredients (APIs) and herbal extracts used in traditional Chinese medicine formulations. It operates primarily through its manufacturing facilities in Hangzhou and distributes products across mainland China, with additional export activities to select Asian markets. Founded in 1993 and headquartered in Hangzhou, Zhejiang Province, the company focuses on the domestic healthcare sector, serving hospitals, pharmacies, and wholesalers as key customer segments. In recent developments within the last two years, Hangzhou TianMuShan has expanded its production capacity through a strategic investment in a new GMP-certified facility for sterile injectables; formed a partnership with a leading biotech firm for co-development of innovative respiratory therapies; and completed a funding round in 2024 to support R&D in oncology drugs, marking a shift toward high-value biologics alongside its traditional herbal portfolio.